Headquartered out of Seville, Spain, and dually focused on advancing biomarker discovery and maintaining operation of Europe’s largest commercial biobank, the synergistic alliance now provides collaborators working with both companies, expanded access to human samples deemed critical in advancing medical research.
Through this agreement, BioServe will now be able to provide customers with access to clinically annotated human specimens from the uniquely homogenous Spanish population.
Featuring a nationwide network capable of acquiring DNA, FFPE’s (fixed formalin paraffin embedded tissue), fluids, and tissues, the NeoCodex biobank continues to grow through continual procurement of samples donated from patients afflicted with the most pharmaceutically relevant disease states, as well as from patients affected with rare neuropsychological disorders.
In return, NeoCodex gains access to BioServe’s Global Repository, a growing library of over 600,000 human DNA, tissue and serum samples linked to detailed clinical and demographic data from 140,000 consented and anonymized patients collected on four continents.
“We are committed to making the Global Repository a prized asset for the life sciences industry by continually providing a data set unparalleled in both its integrity and comprehensiveness. Working with NeoCodex, we further extend the range of DNA and tissue samples that researchers can use to accelerate the development of new diagnostics and drugs in a myriad of diseases,” stated Dr. Kevin Krenitsky, Chief Executive Officer, BioServe.
“We are pleased to enter into this collaboration with BioServe whose Global Repository is widely considered the industry's gold standard for biological samples. With access to the Global Repository, we are able to provide our customers throughout Spain and Europe with case/controls data sets covering most every major disease,” said Dr. Enrique Vázquez Tatay, Chief Executive Officer of NeoCodex.